ApconiX

https://lnkd.in/eU9rg3Z6 This free online event, hosted by Drug Discovery World will outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. Contributors include Ruth Roberts, Dr Sheldon H Preskorn, Mark Treherne, Janet Sasso and Dr Kiri Granger. The showcase will include a panel discussion looking at the use of new drug discovery and development technology, concepts and tools in neuroscience, as well what the future looks like for neuroscience therapies. The showcase will also feature product presentations from sponsors that give the audience the opportunity to learn about the latest technologies driving neuroscience drug discovery and development. What you will learn: · Where is the opportunity in the neuroscience market? · How to uncover the best research tools to boost the development of new treatments · How to recognise and tackle barriers in neuroscience research · What are the technologies that can help create efficiencies and get to market faster? · What does the future hold for neuroscience? Register for free now to secure your place #drugsafety #drugdiscovery

Phumzile Sikakana is attending AusBiotech 2024. Phum is based in Auckland and is excited to meet new colleagues and forge new relationships with biotechnology companies in Australasia. We'd like to thank Dr Patricia Diaz (TCM) for her recent help in reaching out to this region. ApconiX is a team of over 100 nonclinical safety and DMPK experts supporting clients in drug discovery and development, worldwide. Working flexibly, our scientists help identify the key safety questions needed to deliver de risked compounds into clinical trials and through clinical development. We work with clients on the overall safety strategy, deliver the toxicology /DMPK studies, author regulatory documents and support regulatory agency interactions. We combine this toxicology expertise with advanced data science, offering customised Acuity target, modality or asset focused reports, optimising project safety profiles. Our ion channel laboratory conduct hERG and CiPA cardiac screening assays and have developed iSLA an in vitro seizure liability assay. We also carry out research in other fields relevant to efficacy and safety in the CNS #drugsafety #drugdiscovery

https://lnkd.in/eGcA6q8Z Listen to the music of thought and the podcast of the collaborators Ruth Roberts, Kimberly Rockley, Parker Ellingson of Axion BioSystems and Michael Sebastian https://lnkd.in/ekc7EFeg describing the fantastical journey of how the microelectrode array (MEA) electrical signals generated by our in vitro seizure liability assay (iSLA) were turned into music. Many thanks to Paul Gisby https://lnkd.in/ew4Bb2aR for creating the podcast. Also to Austin Passaro also of Axion BioSystems, Magnus Dahlstrand and Andrew Walker and FUJIFILM Cellular Dynamics, Inc #neuroscience2024 #drugsafety #drugdiscovery

Ruth Roberts, and Laurence Bishop at Booth 1277 at Neuroscience 2024 Ruth is presenting today between 2–4:30 p.m. in room MCP Room S105. Theme: Theme B – Neural Excitability, Synapses, and Glia. Seizure and Epilepsy: New Opportunities for Detection and Treatment as Chair and Speaker with Co-Chair (& Speaker) Jennifer Pierson from the Health and Environmental Sciences Institute (HESI). “Seizures occur in treatment-resistant epilepsy and are also a frequent adverse event (AE) in nonclinical and clinical drug development. Studying ion channels and the dynamics of networked brain activity presents the opportunity to develop novel therapeutic options for epilepsy and novel approaches to eliminate seizure liability as an AE. This minisymposium will highlight recent discoveries in the role of ion channels, networks, and multiscale brain activity in detecting, avoiding, and treating seizures.” Tomorrow between 9 and 10 am, C108, Michael Morton is presenting the poster “Benefits of Early In Vitro Screening for Seizure Liability in Problem Solving and Decision Making” authored by Mike, Ruth and Kimberly Rockley #neuroscience2024 #drugsafety #drugdiscovery

https://lnkd.in/eGcA6q8Z Listen to the music of thought and the podcast of the collaborators Ruth Roberts, Kimberly Rockley, Parker Ellingson of Axion BioSystems and Michael Sebastian https://lnkd.in/ekc7EFeg describing the fantastical journey of how the microelectrode array (MEA) electrical signals generated by our in vitro seizure liability assay (iSLA) were turned into music. Many thanks to Paul Gisby https://lnkd.in/ew4Bb2aR for creating the podcast. Also to Austin Passaro also of Axion BioSystems, Magnus Dahlstrand and Andrew Walker and FUJIFILM Cellular Dynamics, Inc #neuroscience2024 #drugsafety #drugdiscovery

Ruth Roberts, Michael Morton and Laurence Bishop are looking forward to welcoming you to Booth 1277 at Neuroscience 2024 next week. Ruth is presenting: Seizure and Epilepsy: New Opportunities for Detection and Treatment as Chair and Speaker with Co-Chair (& Speaker) Jennifer Pierson from the Health and Environmental Sciences Institute (HESI) on Tuesday, October 8, 2–4:30 p.m. in room MCP Room S105. Theme: Theme B – Neural Excitability, Synapses, and Glia. “Seizures occur in treatment-resistant epilepsy and are also a frequent adverse event (AE) in nonclinical and clinical drug development. Studying ion channels and the dynamics of networked brain activity presents the opportunity to develop novel therapeutic options for epilepsy and novel approaches to eliminate seizure liability as an AE. This minisymposium will highlight recent discoveries in the role of ion channels, networks, and multiscale brain activity in detecting, avoiding, and treating seizures.” Mike is presenting the poster “Benefits of Early In Vitro Screening for Seizure Liability in Problem Solving and Decision Making” authored by Mike, Ruth and Kimberly Rockley on Wednesday October 9th between 9 and 10am posterboard number C108 #neuroscience2024 #drugsafety #drugdiscovery

A group of very talented people including Michael Sebastian https://lnkd.in/ekc7EFeg, Kimberly Rockley, Parker Ellingson and Ruth Roberts turned the microelectrode array (MEA) electrical signals generated by our in vitro seizure liability assay (iSLA) into music. Paul Gisby https://lnkd.in/ew4Bb2aR recorded a podcast of the four collaborators describing the fantastical journey. The podcast and the music will be released on Friday in time for Neuroscience 2024. The Society of Neuroscience Annual Meeting will take place in Chicago next week. We'll send out an update on Friday with the link to the music and podcast so you can listen to them both #neuroscience2024 #drugsafety #drugdiscovery

Final Reminder! https://lnkd.in/dYTg2bpK Booking for the Drug Safety Forum 2024: A Patient First Approach to Translational Safety. From Nonclinical to Clinical. Following the success of last year’s Drug Safety Forum, ApconiX has organised Drug Safety Forum 2024, a free to attend, one day symposium on translational safety at the Wellcome Collection, 183 Euston Road, London, on the 17th of October 2024. Speakers include friends and colleagues from AstraZeneca, explic8, Lhasa Limited, ImmunONE and ApconiX. Speakers include Steffen Ernst MD PhD MBA DABT ERT, Peter-Christoph Schulz, Jane Stewart, Dominic Williams, James Sidaway, Adrian Fowkes, Kimberly Rockley, Victoria Hutter and David Jones. Richard Knight will introduce the day. See the (almost final) programme below. The safety of healthy volunteers and patients in clinical trials and, ultimately, our drug products, rely on a complex interplay between many disciplines and functions of which nonclinical drug safety is only one. We call this multidisciplinary construct “Translational Safety”. It only works well when the scientific input is complemented by adequate strategies, operational setups, effective communication, and leadership. We usually hear about Translational Safety when one or more components of this value chain break. Dr Steffen Ernst will give some noteworthy examples in his opening keynote address. This one-day meeting will bring together experts from key pharma safety functions and disciplines, from nonclinical, clinical and regulatory, to discuss current practices, examples and best practice. The day will run from 9am to 5pm with lunch and refreshments provided throughout the day. The meeting will be highly relevant for pharma and biotech industry, scientists, physicians, and regulators. Booking is by invitation. Please contact drug.safety.forum@apconix.com and we will be delighted to send you booking information. We look forward to welcoming you to the Wellcome Collection #drugsafety #drugdiscovery

Kimberly Rockley presented her poster "Benefits of early in vitro screening for seizure liability in problem solving and decision making" at the Safety Pharmacology Society Annual Meeting in San Diego. Kim joined Michael Morton at the conference and received the Carrie Markgraf Blum Women in CNS Travel Award #drugsafety #drugdiscovery

Register for the webinar here https://lnkd.in/efiw3-yi. Hosted by Drug Discovery World and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, MD PhD, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX.   Dr Klein shares how Dewpoint applies insights into the subcellular organisation of biochemical processes into membrane-less compartments to discover novel drug targets and revolutionary drugs for diseases with high unmet need, including amyotrophic lateral sclerosis (ALS) and Rett Syndrome. Dr Clark’s presentation will cover the intersection of medicinal chemistry and drug discovery as well as how this can help address the unmet medical need for new therapeutics in the neuropsych space. Professor Roberts will explore how an integrated in vitro seizure liability assay can benefit drug discovery for companies exploring central nervous system diseases. What you will learn: • Where are the breakthroughs in neuroscience research? • How are advanced technologies proving beneficial to drug discovery and development? • How is the current unmet need within drug discovery and development for central nervous system (CNS) disorders providing opportunity? A Q&A session follows the webinar presentations #drugdiscovery #drugsafety